Phase I/II Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 22 Jul 2017
At a glance
- Drugs Ralimetinib (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms GLYRad
- 18 Jul 2017 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.
- 18 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated